Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis
Authors:
- Tamara N PereiraTPTamara N Pereira
- Meagan J WalshMWMeagan J Walsh
- Peter J LewindonPLPeter J Lewindon
- Grant A RammGRGrant A Ramm
Open Access
- 1 January 2010
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Pathophysiology
- Vol. 1 (2) , 69-84
Abstract
Cholestatic liver disease causes significant morbidity and mortality in children. The diagnosis and management of these diseases can be complicated by an inability to detect early stages of fibrosis and a lack of adequate interventional therapy. There is no single gold standard test that accurately reflects the presence of liver disease, or that can be used to monitor fibrosis progression, particularly in conditions such as cystic fibrosis. This has lead to controversy over how suspected liver disease in children is detected and diagnosed. This review discusses the challenges in using commonly available methods to diagnose hepatic fibrosis and monitor disease progression in children with cholestatic liver disease. In addition, the review examines the mechanisms hypothesised to be involved in the development of hepatic fibrogenesis in paediatric cholestatic liver injury which may ultimately aid in identifying new modalities to assist in both disease detection and therapeutic intervention.Keywords
This publication has 99 references indexed in Scilit:
- Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factorsThe Journal of Pediatrics, 2003
- Genetic induction of proinflammatory immunity in children with biliary atresiaThe Lancet, 2002
- Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-α and TGF-β1Journal of Hepatology, 1999
- The role of TGFβ1 in initiating hepatic stellate cell activation in vivoJournal of Hepatology, 1999
- TGF‐β receptor‐mediated signalling through Smad2, Smad3 and Smad4The EMBO Journal, 1997
- Analysis of risk factors for the development of liver disease associated with cystic fibrosisThe Journal of Pediatrics, 1994
- The changing epidemiology of cystic fibrosisThe Journal of Pediatrics, 1993
- Role of Mesenchymal Cell Populations in Porcine Serum–Induced Rat Liver FibrosisHepatology, 1992
- Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosisThe Journal of Pediatrics, 1990
- Liver Disease and Common-Bile-Duct Stenosis in Cystic FibrosisNew England Journal of Medicine, 1988